Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka
<p>Due to limited access to vaccines, many countries have only administered a single dose of the AZD1222, whereas the dosage intervals have increased ≥4 wk. We sought to investigate the immunogenicity of a single dose of vaccine at ≥16 wk postimmunization. Severe acute respirator...
| मुख्य लेखकों: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| स्वरूप: | Journal article |
| भाषा: | English |
| प्रकाशित: |
American Association of Immunologists
2021
|
| _version_ | 1826310403956670464 |
|---|---|
| author | Jeewandara, C Guruge, D Pushpakumara, PD Kamaladasa, A Aberathna, IS Ramu, ST Gunasekera, B Wijesinghe, A Dissanayake, O Kuruppu, H Ranasinghe, T Jayathilaka, D Dayarathna, S Ekanayake, D Jayamali, J Gamalath, N Mudunkotiwa, A Somathilake, G Dissanayake, M Harvie, M Nimasha, T Madusanka, D Jayadas, T Wijayamuni, R Schimanski, L Rijal, P Tan, TK Townsend, A Ogg, GS Malavige, GN |
| author_facet | Jeewandara, C Guruge, D Pushpakumara, PD Kamaladasa, A Aberathna, IS Ramu, ST Gunasekera, B Wijesinghe, A Dissanayake, O Kuruppu, H Ranasinghe, T Jayathilaka, D Dayarathna, S Ekanayake, D Jayamali, J Gamalath, N Mudunkotiwa, A Somathilake, G Dissanayake, M Harvie, M Nimasha, T Madusanka, D Jayadas, T Wijayamuni, R Schimanski, L Rijal, P Tan, TK Townsend, A Ogg, GS Malavige, GN |
| author_sort | Jeewandara, C |
| collection | OXFORD |
| description | <p>Due to limited access to vaccines, many countries have only administered a single dose of the AZD1222, whereas the dosage intervals have increased ≥4 wk. We sought to investigate the immunogenicity of a single dose of vaccine at ≥16 wk postimmunization. Severe acute respiratory syndrome coronavirus 2–specific Abs in 553 individuals and Abs to the receptor-binding domain of the Wuhan virus (wild-type) and the variants of concern, angiotensin-converting enzyme 2 receptor blocking Abs ex vivo and cultured IFN-γ T cell (<em>Homo sapiens</em>) responses and B cell (<em>H. sapiens</em>) ELISPOT responses, were investigated in a subcohort. The seropositivity rates in those >70 y of age (93.7%) was not significantly different compared with other age groups (97.7–98.2; Pearson χ<sup>2</sup> = 7.8; <em>p</em> = 0.05). The Ab titers (Ab index) significantly declined (<em>p</em> < 0.0001) with increase in age. A total of 18 of 69 (26.1%) of individuals did not have angiotensin-converting enzyme 2 receptor–blocking Abs, whereas responses to the receptor-binding domain of wild-type (<em>p</em> = 0.03), B.1.1.7 (<em>p</em> = 0.04), and B.1.617.2 (<em>p</em> = 0.02) were significantly lower in those who were >60 y. Ex vivo IFN-γ T cell ELISPOT responses were seen in 10 of 66 (15.1%), whereas only a few expressed CD107a. However, >85% had a high frequency of cultured IFN-γ T cell ELISPOT responses and B cell ELISPOTs. Virus-specific Abs were maintained at ≥16 wk after receiving a single dose of AZD1222, although levels were lower to variants of concern, especially in older individuals. A single dose induced a high frequency of memory T and B cell responses.</p> |
| first_indexed | 2024-03-07T07:51:48Z |
| format | Journal article |
| id | oxford-uuid:711af47e-095a-47d9-81b4-92ee2d00e73c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:51:48Z |
| publishDate | 2021 |
| publisher | American Association of Immunologists |
| record_format | dspace |
| spelling | oxford-uuid:711af47e-095a-47d9-81b4-92ee2d00e73c2023-07-19T06:37:41ZImmune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri LankaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:711af47e-095a-47d9-81b4-92ee2d00e73cEnglishSymplectic ElementsAmerican Association of Immunologists2021Jeewandara, CGuruge, DPushpakumara, PDKamaladasa, AAberathna, ISRamu, STGunasekera, BWijesinghe, ADissanayake, OKuruppu, HRanasinghe, TJayathilaka, DDayarathna, SEkanayake, DJayamali, JGamalath, NMudunkotiwa, ASomathilake, GDissanayake, MHarvie, MNimasha, TMadusanka, DJayadas, TWijayamuni, RSchimanski, LRijal, PTan, TKTownsend, AOgg, GSMalavige, GN<p>Due to limited access to vaccines, many countries have only administered a single dose of the AZD1222, whereas the dosage intervals have increased ≥4 wk. We sought to investigate the immunogenicity of a single dose of vaccine at ≥16 wk postimmunization. Severe acute respiratory syndrome coronavirus 2–specific Abs in 553 individuals and Abs to the receptor-binding domain of the Wuhan virus (wild-type) and the variants of concern, angiotensin-converting enzyme 2 receptor blocking Abs ex vivo and cultured IFN-γ T cell (<em>Homo sapiens</em>) responses and B cell (<em>H. sapiens</em>) ELISPOT responses, were investigated in a subcohort. The seropositivity rates in those >70 y of age (93.7%) was not significantly different compared with other age groups (97.7–98.2; Pearson χ<sup>2</sup> = 7.8; <em>p</em> = 0.05). The Ab titers (Ab index) significantly declined (<em>p</em> < 0.0001) with increase in age. A total of 18 of 69 (26.1%) of individuals did not have angiotensin-converting enzyme 2 receptor–blocking Abs, whereas responses to the receptor-binding domain of wild-type (<em>p</em> = 0.03), B.1.1.7 (<em>p</em> = 0.04), and B.1.617.2 (<em>p</em> = 0.02) were significantly lower in those who were >60 y. Ex vivo IFN-γ T cell ELISPOT responses were seen in 10 of 66 (15.1%), whereas only a few expressed CD107a. However, >85% had a high frequency of cultured IFN-γ T cell ELISPOT responses and B cell ELISPOTs. Virus-specific Abs were maintained at ≥16 wk after receiving a single dose of AZD1222, although levels were lower to variants of concern, especially in older individuals. A single dose induced a high frequency of memory T and B cell responses.</p> |
| spellingShingle | Jeewandara, C Guruge, D Pushpakumara, PD Kamaladasa, A Aberathna, IS Ramu, ST Gunasekera, B Wijesinghe, A Dissanayake, O Kuruppu, H Ranasinghe, T Jayathilaka, D Dayarathna, S Ekanayake, D Jayamali, J Gamalath, N Mudunkotiwa, A Somathilake, G Dissanayake, M Harvie, M Nimasha, T Madusanka, D Jayadas, T Wijayamuni, R Schimanski, L Rijal, P Tan, TK Townsend, A Ogg, GS Malavige, GN Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka |
| title | Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka |
| title_full | Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka |
| title_fullStr | Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka |
| title_full_unstemmed | Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka |
| title_short | Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka |
| title_sort | immune responses to a single dose of the azd1222 covishield vaccine at 16 weeks in individuals in sri lanka |
| work_keys_str_mv | AT jeewandarac immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT guruged immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT pushpakumarapd immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT kamaladasaa immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT aberathnais immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT ramust immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT gunasekerab immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT wijesinghea immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT dissanayakeo immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT kuruppuh immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT ranasinghet immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT jayathilakad immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT dayarathnas immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT ekanayaked immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT jayamalij immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT gamalathn immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT mudunkotiwaa immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT somathilakeg immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT dissanayakem immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT harviem immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT nimashat immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT madusankad immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT jayadast immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT wijayamunir immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT schimanskil immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT rijalp immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT tantk immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT townsenda immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT ogggs immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka AT malavigegn immuneresponsestoasingledoseoftheazd1222covishieldvaccineat16weeksinindividualsinsrilanka |